Item 5.02 Disclosure: Regulation FD Disclosure filing by Becton, Dickinson and Company dated February 5, 2026 Securities Listed: The filing references multiple debt instruments including Notes due December 15, 2026 (1.900%), Notes due June 4, 2026 (1.208%), Notes due February 12, 2036 (1.213%), Notes due February 8, 2031 (3.519%), and Notes due June 7, 2032 (3.828%), along with common stock…

Our analysis rates this filing NEUTRAL. Becton Dickinson presents a balanced, stable picture with moderate concerns offset by strategic clarity. The Life Sciences divestiture to Waters represents a material transaction but is already formalized with definitive agreement, reducing execution…

Concern level: ELEVATED (4.2/10). Key factors: One high-severity risk identified: pending Life Sciences divestiture to Waters Corporation creates execution risk and integration complexity; Loss of Life Sciences as reportable segment post-transaction reduces business diversification and segment reporting transparency; Organizational restructuring effective October 1, 2025 requires historical…

Notable risk changes: Organizational restructuring into five new segments effective October 1, 2025 - primarily administrative realignment with no product line changes; Definitive agreement to divest Life Sciences segment (Biosciences and Diagnostic Solutions) to Waters Corporation - reduces future segment count to four; Recast historical financial data provided for FY2025 and quarterly periods under new segment…

The model predicts BDX will underperform the S&P 500 by about 0.1% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.